Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Retreatment with chimeric CD 20 monoclonal antibody in a patient with nodal marginal zone B-cell lymphoma.

Literature DB >> 10962535

Retreatment with chimeric CD 20 monoclonal antibody in a patient with nodal marginal zone B-cell lymphoma.

Abstract

A patient with advanced and chemotherapy-refractory nodal marginal zone B-cell lymphoma was given a course of chimeric CD 20 monoclonal antibody Rituximab. Partial response was observed without any major toxicities. Retreatment with Rituximab for disease progression six months after the first course led to partial remission. Adjuvant radiotherapy was given for the residual disease and, currently, patient's disease remains stable eight months after the second course of Rituximab. This case demonstrates the therapeutic efficacy and feasibility of retreatment with Rituximab for relapsed or refractory low grade lymphoma.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2000 PMID： 10962535 DOI： 10.1007/BF02780533

Source DB: PubMed Journal: Med Oncol ISSN： 1357-0560 Impact factor: 3.064

12 in total

1. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8).

Authors: U Winkler; M Jensen; O Manzke; H Schulz; V Diehl; A Engert
Journal: Blood Date: 1999-10-01 Impact factor: 22.113

2. Fatal cytokine release syndrome with chimeric anti-CD20 monoclonal antibody rituximab in a 71-year-old patient with chronic lymphocytic leukemia.

Authors: L C Lim; L P Koh; P Tan
Journal: J Clin Oncol Date: 1999-06 Impact factor: 44.544

3. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy.

Authors: M S Czuczman; A J Grillo-López; C A White; M Saleh; L Gordon; A F LoBuglio; C Jonas; D Klippenstein; B Dallaire; C Varns
Journal: J Clin Oncol Date: 1999-01 Impact factor: 44.544

4. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP).

Authors: W S Velasquez; F Cabanillas; P Salvador; P McLaughlin; M Fridrik; S Tucker; S Jagannath; F B Hagemeister; J R Redman; F Swan
Journal: Blood Date: 1988-01 Impact factor: 22.113

5. Advanced lymphosarcoma: intensive cyclical combination chemotherapy with cyclophosphamide, vincristine, and prednisone.

Authors: C M Bagley; V T Devita; C W Berard; G P Canellos
Journal: Ann Intern Med Date: 1972-02 Impact factor: 25.391

10. Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab).

Authors: M Jensen; U Winkler; O Manzke; V Diehl; A Engert
Journal: Ann Hematol Date: 1998 Jul-Aug Impact factor: 3.673

1 in total

Review 1. Management of marginal zone lymphomas.

Authors: Catherine Thieblemont; Bertrand Coiffier
Journal: Curr Treat Options Oncol Date: 2006-05

1 in total

Retreatment with chimeric CD 20 monoclonal antibody in a patient with nodal marginal zone B-cell lymphoma.

1. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8).

2. Fatal cytokine release syndrome with chimeric anti-CD20 monoclonal antibody rituximab in a 71-year-old patient with chronic lymphocytic leukemia.

3. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy.

4. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP).

5. Advanced lymphosarcoma: intensive cyclical combination chemotherapy with cyclophosphamide, vincristine, and prednisone.

6. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab.

7. EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma.

Review 8. Nodal monocytoid B-cell lymphoma (nodal marginal-zone B-cell lymphoma).

9. IMVP-16: an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy.

10. Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab).

Review 1. Management of marginal zone lymphomas.